JP2011526596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526596A5 JP2011526596A5 JP2011515445A JP2011515445A JP2011526596A5 JP 2011526596 A5 JP2011526596 A5 JP 2011526596A5 JP 2011515445 A JP2011515445 A JP 2011515445A JP 2011515445 A JP2011515445 A JP 2011515445A JP 2011526596 A5 JP2011526596 A5 JP 2011526596A5
- Authority
- JP
- Japan
- Prior art keywords
- modulator
- alkyl
- hydrogen
- dopa
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 9
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 9
- 208000018737 Parkinson disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 6
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 claims 6
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 6
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 claims 6
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 4
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 229940052760 dopamine agonists Drugs 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 229960003587 lisuride Drugs 0.000 claims 1
- 229940124807 mGLUR antagonist Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical group C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7677208P | 2008-06-30 | 2008-06-30 | |
| US61/076,772 | 2008-06-30 | ||
| PCT/EP2009/058230 WO2010000763A2 (en) | 2008-06-30 | 2009-06-30 | Combination products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526596A JP2011526596A (ja) | 2011-10-13 |
| JP2011526596A5 true JP2011526596A5 (enExample) | 2012-08-16 |
Family
ID=41112516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515445A Pending JP2011526596A (ja) | 2008-06-30 | 2009-06-30 | 組み合わせ製品 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8703809B2 (enExample) |
| EP (2) | EP2320892A2 (enExample) |
| JP (1) | JP2011526596A (enExample) |
| KR (1) | KR20110027817A (enExample) |
| CN (2) | CN102131503A (enExample) |
| AU (1) | AU2009265760B2 (enExample) |
| BR (1) | BRPI0913642A2 (enExample) |
| CA (1) | CA2729595C (enExample) |
| MX (1) | MX2010014222A (enExample) |
| RU (1) | RU2496494C2 (enExample) |
| WO (1) | WO2010000763A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2211859B1 (en) * | 2007-10-12 | 2016-01-06 | Novartis AG | Metabotropic glutamate receptor modulators for the treatment of parkinson's disease |
| MY151183A (en) * | 2008-08-12 | 2014-04-30 | Novartis Ag | Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof |
| EP2655326A1 (en) * | 2010-12-20 | 2013-10-30 | Novartis AG | 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters |
| GB201204962D0 (en) | 2012-03-21 | 2012-05-02 | Addex Pharmaceuticals Sa | Pharmaceutical combination products for parkinsons disease |
| MX2021014782A (es) | 2012-10-22 | 2023-03-23 | Civitas Therapeutics Inc | Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson. |
| JP5744112B2 (ja) * | 2013-06-11 | 2015-07-01 | デクセリアルズ株式会社 | パターン形成体の製造方法 |
| GB201312800D0 (en) | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
| EP3134077A4 (en) * | 2014-04-21 | 2017-12-20 | Civitas Therapeutics, Inc. | Rapid relief of motor fluctuations in parkinson's disease |
| AU2018310881C1 (en) * | 2017-07-31 | 2021-12-16 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
| JP2020529978A (ja) * | 2017-07-31 | 2020-10-15 | ノバルティス アーゲー | アルコール使用の低減又はアルコール使用再燃の予防におけるマボグルラントの使用 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769424A (en) * | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| US5521297A (en) | 1993-06-04 | 1996-05-28 | Salk Institute Biotechnology/Industrial Associates | Nucleic acids encoding human metabotropic glutamate receptors |
| FR2777781B1 (fr) * | 1998-04-24 | 2004-04-09 | Rhone Poulenc Rorer Sa | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson |
| GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
| CN1894241A (zh) | 2002-08-09 | 2007-01-10 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑 |
| US7105533B2 (en) * | 2002-09-13 | 2006-09-12 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
| CN1794990A (zh) * | 2003-04-04 | 2006-06-28 | 麦克公司 | 代谢型谷氨酸受体－5的二芳基取代吡咯调节剂 |
| TWI287010B (en) | 2003-06-12 | 2007-09-21 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| US20060281803A1 (en) * | 2003-09-23 | 2006-12-14 | Lindsley Craig W | Pyrazole modulators of metabotropic glutamate receptors |
| EP1677790A1 (en) | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes ii |
| EP1677789A1 (en) | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes i |
| EP1677788A1 (en) | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes iii |
| CN1933838A (zh) | 2004-02-12 | 2007-03-21 | 默克公司 | 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺 |
| CN1954543A (zh) | 2004-04-14 | 2007-04-25 | 数码河股份有限公司 | 基于地理位置的许可系统 |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| TW200801005A (en) | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Acetylenic piperazines as metabotropic glutamate receptor antagonists |
| US20090005363A1 (en) * | 2005-12-20 | 2009-01-01 | Ralf Glatthar | Organic Compounds |
| AU2007256931B2 (en) | 2006-05-30 | 2013-01-24 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor |
| KR20090033871A (ko) * | 2006-06-16 | 2009-04-06 | 솔베이 파마슈티칼스 비. 브이 | 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제 |
| MX2009001036A (es) | 2006-08-04 | 2009-04-23 | Merz Pharma Gmbh & Co Kgaa | Pirazolopirimidinas, proceso para su preparacion y su uso como medicina. |
| MX2009002684A (es) * | 2006-09-11 | 2009-06-05 | Novartis Ag | Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico. |
| EP2211859B1 (en) | 2007-10-12 | 2016-01-06 | Novartis AG | Metabotropic glutamate receptor modulators for the treatment of parkinson's disease |
-
2009
- 2009-06-30 KR KR1020117002251A patent/KR20110027817A/ko not_active Ceased
- 2009-06-30 RU RU2011103083/15A patent/RU2496494C2/ru not_active IP Right Cessation
- 2009-06-30 CN CN2009801331117A patent/CN102131503A/zh active Pending
- 2009-06-30 JP JP2011515445A patent/JP2011526596A/ja active Pending
- 2009-06-30 WO PCT/EP2009/058230 patent/WO2010000763A2/en not_active Ceased
- 2009-06-30 CA CA2729595A patent/CA2729595C/en not_active Expired - Fee Related
- 2009-06-30 US US12/999,634 patent/US8703809B2/en not_active Expired - Fee Related
- 2009-06-30 CN CN2013101485895A patent/CN103212078A/zh active Pending
- 2009-06-30 BR BRPI0913642A patent/BRPI0913642A2/pt not_active IP Right Cessation
- 2009-06-30 EP EP09772463A patent/EP2320892A2/en not_active Withdrawn
- 2009-06-30 MX MX2010014222A patent/MX2010014222A/es not_active Application Discontinuation
- 2009-06-30 AU AU2009265760A patent/AU2009265760B2/en not_active Ceased
- 2009-06-30 EP EP14167553.8A patent/EP2826478A1/en not_active Withdrawn
-
2014
- 2014-03-04 US US14/195,947 patent/US20140194423A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526596A5 (enExample) | ||
| RU2011103083A (ru) | Комбинации, содержащие модуляторы mglur, для лечения болезни паркинсона | |
| NZ590268A (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
| JP2015510886A5 (enExample) | ||
| JP2016529245A5 (enExample) | ||
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| JP2008516986A5 (enExample) | ||
| JP2013521286A5 (enExample) | ||
| JP2008531599A5 (enExample) | ||
| GEP20156250B (en) | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
| TW200602043A (en) | Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria | |
| JP2009507896A5 (enExample) | ||
| JP2008501000A5 (enExample) | ||
| JP2017528467A5 (enExample) | ||
| JP2013521288A5 (enExample) | ||
| WO2007103970A3 (en) | Compositions and methods for treating respiratory disorders | |
| JP2014505107A5 (enExample) | ||
| NZ601077A (en) | Use of an adrenal hormone-modifying agent | |
| MA32460B1 (fr) | Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases | |
| JP2014511374A5 (enExample) | ||
| JP2011529502A5 (enExample) | ||
| JP2015522032A5 (enExample) | ||
| JP2010155827A5 (enExample) | ||
| RU2012120759A (ru) | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы | |
| JP2016529235A5 (enExample) |